Denali Launches With Big Fund-Raising | Chemical & Engineering News
Volume 93 Issue 20 | p. 17 | Concentrates
Issue Date: May 18, 2015

Denali Launches With Big Fund-Raising

Department: Business
Keywords: neurodegenerative diseases, Alzheimer’s

Denali Therapeutics, a new biotech firm focused on neurodegenerative disease, has launched with an initial investment commitment of $217 million, an amount being called the largest ever for a biotech firm. Denali’s three founders—Ryan Watts, Alexander Schuth, and Marc Tessier-Lavigne—are all former Genentech scientists. Notably, Tessier-Lavigne, now president of Rocke­feller University, led R&D at Genentech during the 2000s. Denali says it plans to discover medicines for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other neurodegenerative ailments.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment